{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:21:50Z","timestamp":1793733710304,"version":"4.6.1"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Prolactin (PRL) is a peptide hormone mainly secreted from the anterior pituitary gland. PRL is reported to play a role in pregnancy, mammary gland development, immune modulation, reproduction, and differentiation of islet cells. PRL binds to its receptor PRLR, which belongs to a superfamily of the class I cytokine receptor that has no intrinsic kinase activity. In canonical signaling, PRL binding to PRLR induces downstream signaling including JAK-STAT, AKT and MAPK pathways. This leads to increased cell proliferation, stemness, migration, apoptosis inhibition, and resistance to chemotherapy. PRL-signaling is upregulated in numerous hormone-dependent cancers including breast, prostate, ovarian, and endometrial cancer. However, more recently, the pathway has been reported to play a tumor-promoting role in other cancer types such as colon, pancreas, and hepatocellular cancers. Hence, the signaling pathway is an attractive target for drug development with blockade of the receptor being a potential therapeutic approach. Different strategies have been developed to target this receptor including modification of PRL peptides (Del1-9-G129R-hPRL, G129R-Prl), growth hormone receptor\/prolactin receptor bispecific antibody antagonist, neutralizing antibody LFA102, an antibody-drug conjugate (ABBV-176) of the humanized antibody h16f (PR-1594804) and pyrrolobenzodiazepine dimer, a bispecific antibody targeting both PRLR and CD3, an\n                    <jats:italic>in vivo<\/jats:italic>\n                    half-life extended fusion protein containing PRLR antagonist PrlRA and albumin binding domain. There have also been attempts to discover and develop small molecular inhibitors targeting PRLR. Recently, using structure-based virtual screening, we identified a few antipsychotic drugs including penfluridol as a molecule that inhibits PRL-signaling to inhibit PDAC tumor progression. In this review, we will summarize the recent advances in the biology of this receptor in cancer and give an account of PRLR antagonist development for the treatment of cancer.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2022.1112987","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:46Z","timestamp":1673568046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies"],"prefix":"10.3389","volume":"13","author":[{"given":"David","family":"Standing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Dandawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Anant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","first-page":"3","article-title":"Prolactin biology and laboratory measurement: An update on physiology and current analytical issues","volume":"39","author":"Saleem","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2007-0017","article-title":"What can we learn from rodents about prolactin in humans","volume":"29","author":"Ben-Jonathan","year":"2008","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(02)00603-3","article-title":"Prolactin as an autocrine\/paracrine growth factor in human cancer","volume":"13","author":"Ben-Jonathan","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.24.14353","article-title":"Characterization of lactogen receptor-binding site 1 of human prolactin","volume":"271","author":"Kinet","year":"1996","journal-title":"J Biol Chem"},{"key":"B5","article-title":"Alanine-scanning mutagenesis of human prolactin: Importance of the 58-74 region for bioactivity","volume":"6","author":"Goffin","year":"1992","journal-title":"Mol Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.28.16573","article-title":"Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay","volume":"271","author":"Goffin","year":"1996","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)31676-4","article-title":"Evidence for a second receptor binding site on human prolactin","volume":"269","author":"Goffin","year":"1994","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.089128","article-title":"Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2","volume":"285","author":"Broutin","year":"2010","journal-title":"J Biol Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1066","article-title":"Human prolactin gene promoter regulation by estrogen: Convergence with tumor necrosis factor-alpha signaling","volume":"149","author":"Adamson","year":"2008","journal-title":"Endocrinology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/bies.20468","article-title":"Prolactin in man: A tale of two promoters","volume":"28","author":"Gerlo","year":"2006","journal-title":"Bioessays"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/gad.204636.112","article-title":"Autocrine prolactin: An emerging market for homegrown (prolactin) despite the imports","volume":"26","author":"Muthuswamy","year":"2012","journal-title":"Genes Dev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025537","article-title":"Dopamine receptors in human adipocytes: expression and functions","volume":"6","author":"Borcherding","year":"2011","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2012.02310.x","article-title":"The prolactin gene: A paradigm of tissue-specific gene regulation with complex temporal transcription dynamics","volume":"24","author":"Featherstone","year":"2012","journal-title":"J Neuroendocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.949396","article-title":"Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness","volume":"13","author":"Kavarthapu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00184","article-title":"Prolactin: The bright and the dark side","volume":"158","author":"Lopez Vicchi","year":"2017","journal-title":"Endocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184685","article-title":"Crosstalk between PRLR and EGFR\/HER2 signaling pathways in breast cancer","volume":"13","author":"Kavarthapu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1533","article-title":"Prolactin activates ERalpha in the absence of ligand in female mammary development and carcinogenesis in vivo","volume":"154","author":"O\u2019Leary","year":"2013","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.473","article-title":"Activation of the unliganded estrogen receptor by prolactin in breast cancer cells","volume":"28","author":"Gonzalez","year":"2009","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1758","article-title":"Synergistic activation of ERalpha by estrogen and prolactin in breast cancer cells requires tyrosyl phosphorylation of PAK1","volume":"76","author":"Oladimeji","year":"2016","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11579","article-title":"Role of EGF\/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells","volume":"7","author":"Kavarthapu","year":"2016","journal-title":"Oncotarget"},{"key":"B22","article-title":"Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells","volume":"9","author":"MacDonald","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.910978","article-title":"Prolactin: The third hormone in breast cancer","volume":"13","author":"Schuler","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.747810","article-title":"The relevant participation of prolactin in the genesis and progression of gynecological cancers","volume":"12","author":"Ramirez-de-Arellano","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1053\/j.gastro.2019.11.279","article-title":"Diphenylbutylpiperidine antipsychotic drugs inhibit prolactin receptor signaling to reduce growth of pancreatic ductal adenocarcinoma in mice","volume":"158","author":"Dandawate","year":"2020","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/carcin\/bgt379","article-title":"Prolactin signaling enhances colon cancer stemness by modulating notch signaling in a Jak2-STAT3\/ERK manner","volume":"35","author":"Neradugomma","year":"2014","journal-title":"Carcinogenesis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4652","article-title":"Biological significance of prolactin in gynecologic cancers","volume":"69","author":"Levina","year":"2009","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-017-0292-7","article-title":"Growth hormone receptor knockdown sensitizes human melanoma cells to chemotherapy by attenuating expression of ABC drug efflux pumps","volume":"8","author":"Basu","year":"2017","journal-title":"Horm Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1124\/mol.112.082362","article-title":"Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells","volume":"83","author":"Wu","year":"2013","journal-title":"Mol Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.celrep.2014.03.009","article-title":"Antagonism of tumoral prolactin receptor promotes autophagy-related cell death","volume":"7","author":"Wen","year":"2014","journal-title":"Cell Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0839","article-title":"Preclinical activity of the novel anti-prolactin receptor (PRLR) antibody-drug conjugate REGN2878-DM1 in PRLR-positive breast cancers","volume":"16","author":"Kelly","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0270","article-title":"Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305687200","article-title":"Development of pure prolactin receptor antagonists","volume":"278","author":"Bernichtein","year":"2003","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0092-8674(88)90488-6","article-title":"Cloning and expression of the rat prolactin receptor, a member of the growth hormone\/prolactin receptor gene family","volume":"53","author":"Boutin","year":"1988","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5061","article-title":"Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice","volume":"87","author":"Chen","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/endo-129-3-1402","article-title":"Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice","volume":"129","author":"Chen","year":"1991","journal-title":"Endocrinology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.36.21969","article-title":"Long-acting growth hormones produced by conjugation with polyethylene glycol","volume":"271","author":"Clark","year":"1996","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(01)00461-1","article-title":"Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly","volume":"12","author":"Drake","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"B39","article-title":"Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer","volume":"86","author":"Ross","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/bi049333p","article-title":"Mechanism for ordered receptor binding by human prolactin","volume":"43","author":"Sivaprasad","year":"2004","journal-title":"Biochemistry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.16.9222","article-title":"G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells","volume":"270","author":"Dattani","year":"1995","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.2.8593788","article-title":"The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor","volume":"137","author":"Mode","year":"1996","journal-title":"Endocrinology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.8.7047","article-title":"The human growth hormone antagonist B2036 does not interact with the prolactin receptor","volume":"140","author":"Goffin","year":"1999","journal-title":"Endocrinology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203846","article-title":"Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation","volume":"19","author":"Llovera","year":"2000","journal-title":"Oncogene"},{"key":"B45","article-title":"A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis","volume":"5","author":"Chen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ijo.18.1.25","article-title":"In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells","volume":"18","author":"Ramamoorthy","year":"2001","journal-title":"Int J Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.17.6.1179","article-title":"Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells","volume":"17","author":"Cataldo","year":"2000","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:20:1-2:177","article-title":"New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity","volume":"20","author":"Bernichtein","year":"2003","journal-title":"Endocrine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.20.4.813","article-title":"In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R","volume":"20","author":"Chen","year":"2002","journal-title":"Int J Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-004-4816-9","article-title":"Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of pseudomonas exotoxin a","volume":"90","author":"Langenheim","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"B51","article-title":"Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer","volume":"63","author":"Beck","year":"2003","journal-title":"Cancer Res"},{"key":"B52","article-title":"A novel design of targeted endocrine and cytokine therapy for breast cancer","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B53","article-title":"Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2\/neu transgenic mice","volume":"34","author":"Tomblyn","year":"2009","journal-title":"Int J Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9789-z","article-title":"Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells","volume":"111","author":"Scotti","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocr Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704364200","article-title":"Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL","volume":"282","author":"Jomain","year":"2007","journal-title":"J Biol Chem"},{"key":"B57","first-page":"385","article-title":"Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals","volume":"17","author":"Goffin","year":"1996","journal-title":"Endocr Rev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0303-7207(03)00264-8","article-title":"The n-terminus of human prolactin modulates its biological properties","volume":"208","author":"Bernichtein","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097383","article-title":"Prolactin induces apoptosis of lactotropes in female rodents","volume":"9","author":"Ferraris","year":"2014","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16242","article-title":"Hematopoietic PBX-interacting protein is a novel regulator of mammary epithelial cell differentiation","volume":"289","author":"Dwivedi","year":"2022","journal-title":"FEBS J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13568-021-01209-5","article-title":"Periplasmic synthesis and purification of the human prolactin antagonist \u0394(1-11)-G129R-hPRL","volume":"11","author":"Suzuki","year":"2021","journal-title":"AMB Express"},{"key":"B62","article-title":"Prolactin and androgen R1881 induce pro-survival carboxypeptidase-d and EDD E3 ligase in triple-negative and HER2+ breast cancer","volume":"10","author":"MacDonald","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv338","article-title":"The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation","volume":"108","author":"Sutherland","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23054","article-title":"Prolactin- and testosterone-induced carboxypeptidase-d correlates with increased nitrotyrosines and Ki67 in prostate cancer","volume":"75","author":"Thomas","year":"2015","journal-title":"Prostate"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1660","article-title":"The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells","volume":"41","author":"Hou","year":"2012","journal-title":"Int J Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr2129","article-title":"Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity","volume":"10","author":"Howell","year":"2008","journal-title":"Breast Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"19578","DOI":"10.1038\/s41598-019-55860-x","article-title":"Prolactin and its receptor as therapeutic targets in glioblastoma multiforme","volume":"9","author":"Asad","year":"2019","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911651107","article-title":"Local prolactin is a target to prevent expansion of basal\/stem cells in prostate tumors","volume":"107","author":"Rouet","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B69","doi-asserted-by":"publisher","first-page":"54S","DOI":"10.1177\/0091270011413894","article-title":"Characterizing the impact of renal impairment on the clinical pharmacology of biologics","volume":"52","author":"Meibohm","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"B70","article-title":"[A kinetic study on serum prolactin concentration in the thyrotropin-releasing hormone test]","volume":"28","author":"Yoshida","year":"1991","journal-title":"Kaku Igaku"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215831","article-title":"An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation","volume":"14","author":"Yu","year":"2019","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B74","volume-title":"Encylopedia of immunology","author":"Van den Eynde","year":"1998"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611693104","article-title":"A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors","volume":"104","author":"Scott","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3270","article-title":"Antibody\u2013drug conjugates for cancer: poised to deliver","volume":"9","author":"Hughes","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: Versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-010-0501-0","article-title":"C-MET as a new therapeutic target for the development of novel anticancer drugs","volume":"12","author":"Ca\u00f1adas","year":"2010","journal-title":"Clin Trans Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/life12010130","article-title":"A comparative and comprehensive review of antibody applications in the treatment of lung disease","volume":"12","author":"Wu","year":"2022","journal-title":"Life (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for b-cell non-hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature09339","article-title":"Translating cancer research into targeted therapeutics","volume":"467","author":"de Bono","year":"2010","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Scie"},{"key":"B88","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/1535-7163.MCT-12-0886","article-title":"Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer","volume":"12","author":"Damiano","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0502","article-title":"Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer","volume":"21","author":"Agarwal","year":"2016","journal-title":"Oncologist"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14526","article-title":"Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer","volume":"40","author":"Minami","year":"2020","journal-title":"Anticancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2016.11.015","article-title":"Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist","volume":"95","author":"Cui","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12885-021-08403-5","article-title":"ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition","volume":"21","author":"Anderson","year":"2021","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00960-z","article-title":"A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors","volume":"38","author":"Lemech","year":"2020","journal-title":"Invest New Drugs"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific antibodies: From research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-017-08641-3","article-title":"Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2018.10.001","article-title":"Naturally split intein npu DnaE mediated rapid generation of bispecific IgG antibodies","volume":"154","author":"Han","year":"2019","journal-title":"Methods"},{"key":"B97","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-020-01564-4","article-title":"A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer","volume":"39","author":"Zhou","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1297","article-title":"The role of prolactin receptor in GH signaling in breast cancer cells","volume":"27","author":"Xu","year":"2013","journal-title":"Mol Endocrinol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1210\/me.2010-0255","article-title":"Growth hormone signaling in human T47D breast cancer cells: Potential role for a growth hormone receptor-prolactin receptor complex","volume":"25","author":"Xu","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.598423","article-title":"Preparation of a growth hormone Receptor\/Prolactin receptor bispecific antibody antagonist which exhibited anti-cancer activity","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011613-140028","article-title":"Targeting protein-protein interaction by small molecules","volume":"54","author":"Jin","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112662","article-title":"Suppression of breast cancer by small molecules that block the prolactin receptor","volume":"13","author":"Borcherding","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.02.015","article-title":"Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer chemical research laboratory","volume":"27","author":"Beck","year":"2022","journal-title":"Drug Discov Today"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1112987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:56Z","timestamp":1673568056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1112987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":103,"alternative-id":["10.3389\/fendo.2022.1112987"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1112987","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1112987"}}